Ocular Toxicity Appears Common With Belantamab Mafodotin in Advanced Multiple Myeloma

Source: Myeloma – Hematology Advisor

Researchers sought to determine whether ocular toxicity occurred in a significant number of patients with multiple myeloma treated with belantamab mafodotin.
Read More